Search results
We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
Simply Wall St. via Yahoo Finance· 18 hours agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross?
Zacks via Yahoo Finance· 1 year agoStoke Therapeutics, Inc. (STOK) is looking like an interesting pick from a technical perspective, as...
Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts...
Zacks via Yahoo Finance· 4 months agoThe mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in...
Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment
GuruFocus.com via Yahoo Finance· 7 months agoStoke Therapeutics Inc (NASDAQ:STOK) anticipates Q1 2024 readout for Phase 1/2a study results of...
Racecourse Ground refreshed as Wrexham partner with US cold brew coffee brand
PA Media: Sport via Yahoo Sports· 1 year agoWrexham’s historic Racecourse Ground will become known as the SToK Racecourse under the terms of a...
Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks via Yahoo Finance· 2 years agoAfter losing some value lately, a hammer chart pattern has been formed for Stoke Therapeutics, Inc....
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Zacks via Yahoo Finance· 3 months agoStoke Therapeutics, Inc. STOK reported encouraging new data from two phase I/IIa studies and two...
Wrexham to expand temporary stand after 'reassessing' stadium plans
BBC via Yahoo Sports· 17 hours agoWrexham regularly sell out the Racecourse Ground for matches [Huw Evans Picture Agency] Wrexham say...
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting...
Simply Wall St. via Yahoo Finance· 1 year agoStoke Therapeutics, Inc. (NASDAQ:STOK) defied analyst predictions to release its first-quarter...
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoStoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%,...